| |
Patients included February through December 1999
|
Patients included February 2000 through June 2001
|
Adherence to therapy after 1 year (2 years)
|
Hazard ratio (95% CI)
|
Hazard ratio (95% CI), time-dependent Cox regression analysis
|
|---|
|
Etanercept and MTX
|
58
|
5a
|
90% (87%)
|
3.27 (1.76; 6.08)
|
3.15 (1.84; 5.39)
|
|
Infliximab and MTX
|
12a
|
206
|
68% (60%)
| | |
|
Etanercept as monotherapy
|
100
|
13a
|
77% (69%)
|
4.26 (2.60; 7.00)
|
2.75 (1.70; 4.46)
|
|
Infliximab as monotherapy
|
0a
|
56
|
45% (27%)
| | |
- aPatients not included in analysis. The hazard ratios were adjusted for differences in age, gender, 28-joint disease activity score (DAS28), health assessment questionnaire (HAQ) score, disease duration, previous disease-modifying antirheumatic drugs, and C-reactive protein (CRP) level. Data presented in the last column use HAQ score, DAS28, and CRP level as time-dependent covariates. For details, see Results. CI, confidence interval; MTX, methotrexate.
